Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adagrasib + afatinib
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination therapy of **adagrasib** (a selective, irreversible inhibitor of KRAS G12C mutation; developed primarily for advanced solid tumors) and **afatinib** (an irreversible pan-ERBB and EGFR family tyrosine kinase inhibitor), being studied for synergistic antitumor effects and overcoming resistance to KRAS inhibition[1][3][6]. Adagrasib blocks mutant KRAS signaling; afatinib binds nonreversibly to the ERBB receptor family, broadly inhibiting EGFR, HER2, and related pathways to prevent compensatory resistance. Together, this dual inhibition more effectively clears tumors and prevents/drives regression of resistance, notably in preclinical pancreatic cancer models[1]. No marketed combination product; clinical investigation is ongoing[1][3].
- Brand names
- Krazati (adagrasib)Gilotrif (afatinib)
- Other names
- adagrasib + afatinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on adagrasib + afatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adagrasib + afatinib.